News

The nanoformulation developed by the Smart4Fabry EU project has been designated as Orphan Drug

We are proud to announce that the new nanoformulation developed by Smart4Fabry for the treatment of Fabry disease has achieved the ODD (Orphan Drug Designation) by the European Commission.
The new nanomedicine is more effective and has a better biodistribution than the current treatments, based on enzyme replacement. The new nanomedicine is based on a nanovesicle that protects the enzyme and achieves a better cell internalisation, thus reducing the doses needed, the total cost and improving the quality of patients.